KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
03 Abril 2023 - 8:35AM
Business Wire
Alzamend Neuro, Inc. requests that their press release
NewsItemId: 20230403005455 “Alzamend Neuro Receives FDA “Study May
Proceed” Letter for Phase I/IIA Trial Under Its Investigational New
Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat
Mild to Moderate Dementia of the Alzheimer’s Type” be killed.
The release was issued in error by Alzamend Neuro, Inc.
A replacement release was issued on April 3, 2023, at 08:50 AM
Eastern Time.
Email: Info@Alzamend.com or call: 1-844-722-6333
Alzamend Neuro (NASDAQ:ALZN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Alzamend Neuro (NASDAQ:ALZN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
